ClinicalTrials.gg
RecruitingNCT07845487ASCENTRA-UCUpdated Nov 12, 2026

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2 interventional study of PALI-2108 and PALI-2108 in Ulcerative Colitis (UC), Severe Ulcerative Colitis and Moderate Ulcerative Colitis, sponsored by Palisade Bio. Recruiting at 114 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Palisade Bio · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 12, 2026Site recruiting status changedNewly registered+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Planned enrollment
137th of 499
204 · median 76
Started
2026
with 41 others
Phase 2
146 of 615
25 open now
Primary completion
2027-10
later than 93 of 165 live
Registered
614th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 137th largest by planned enrollment of the 499 interventional ones that give a count, is one of 42 that started in 2026, is one of 146 in phase 2, reaches primary completion later than 93 of the 165 other live ones, and was the 614th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

The ASCENTRA-UC study is a phase 2 study testing PALI-2108 in patients with moderate to severe ulcerative colitis. Doses of drug will be compared against a placebo to see how well it works, how safe it is, and how the body responds to it.

03

Conditions studied

  • Ulcerative Colitis (UC)
  • Severe Ulcerative Colitis
  • Moderate Ulcerative Colitis

Keywords

  • Colitis
  • Ulcerative Colitis
  • Inflammatory Bowel Disease
  • IBD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented clinical diagnosis of UC for ≥ 3 months prior to Screening. The diagnosis of UC must be confirmed by endoscopic and histologic evidence.

    • If a histopathology report is not available in the source records, a for a local histopathology evaluation (to obtain a report) can be obtained during the screening endoscopy procedure.
  • Moderately to severely active UC, defined as:

    • mMS of 5 to 9 (inclusive), AND
    • ES ≥ 2, AND
    • RB ≥ 1.
  • Participants must satisfy at least one of the criteria listed under item a OR at least one of the criteria listed under item b:

    a. History of inadequate response or loss of response, or intolerance to at least one prior UC therapy, defined as: i. Oral prednisone ≥ 40 mg/day (or equivalent) or budesonide ≥ 9 mg/day for ≥ 2 weeks.

ii. dependence: unable to taper \< 10 mg/day prednisone equivalent within 3 months, or relapse within 3 months of discontinuation.

iii. : azathioprine ≥ 2 mg/kg/day, 6-mercaptopurine (6-MP) ≥ 1.0 mg/kg/day (or therapeutic 6-thioguanine nucleotide [6-TGN] level) for ≥ 12 weeks, or methotrexate ≥ 15 mg/week subcutaneous or intramuscular.

iv. Approved advanced therapies at the approved labelled dose:

  1. Anti-tumor necrosis factor (TNF), anti-integrin (vedolizumab), or anti-IL-12/23 for at least 8 weeks; anti-IL 23 for at least 12 weeks.
  2. Janus kinase (JAK) inhibitor for at least 8 weeks; sphingosine-1-phosphate receptor (S1PR) modulator for at least 12 weeks.

Note: Demonstration of intolerance requires no minimum dose nor duration of use.

b. Currently receiving one or more of the following treatments: i. Stable oral prednisone at ≤ 20 mg/day (or equivalent) or budesonide ≤ 9 mg for ≥ 2 weeks prior to randomization.

ii. Stable dose of thiopurine (azathioprine or 6-MP) for ≥ 4 weeks prior to randomization, and have started the treatment ≥ 12 weeks prior to randomization.

iii. Stable dose of oral aminosalicylates for ≥ 2 weeks prior to randomization.

Key Exclusion Criteria:• Diagnosis of Crohn's disease or IBD-Unclassified (IBD-U; indeterminate colitis) or a history of ischemic colitis or radiation colitis.

  • UC limited to rectum (\< 15 cm from anal verge).
  • Any prior history of suicidal behavior (actual, interrupted, aborted attempt, or preparatory acts).
  • Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation type 4 or 5, or any active suicidal ideation with some intent to act.
  • Severe depression at Screening based on a validated scale threshold (e.g., Patient Health Questionnaire-9 [PHQ-9] ≥ 20, or PHQ-9 item 9 > 0) at Screening.
  • Failure or intolerance of > 3 classes of approved advanced therapies or > 4 approved individual advanced therapies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    PALI-2108 Dose 1

    15mg QD

    Drug: PALI-2108

  • Experimental
    PALI-2108 Dose 2

    30mg QD

    Drug: PALI-2108

  • Placebo comparator
    Placebo

    QD

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with clinical remission using the 3-component modified Mayo Score (mMS) at Week 12.

    The Modified Mayo Score (MMS) is a composite score of ulcerative colitis (UC) disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: Endoscopic subscore (ES), scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); Stool frequency subscore (SFS), scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and rectal bleeding subscore (RBS), scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS.

    Time frame: Week 12

Secondary outcomes

  1. Proportion of participants with clinical response using 3-component mMS at Week 12.

    The Modified Mayo Score (MMS) is a composite score of ulcerative colitis (UC) disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: Endoscopic subscore (ES), scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); Stool frequency subscore (SFS), scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and rectal bleeding subscore (RBS), scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS.

    Time frame: At 12 weeks

  2. Proportion of participants with endoscopic improvement at Week 12.

    Endoscopic improvement is defined as Mayo endoscopic subscore (ES) of 0 or 1. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity.

    Time frame: Week 12

  3. Proportion of participants with HEMI at Week 12.

    HEMI is defined as a Geboes score of 3.1 or less and ES of 0 or 1. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation. ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration).

    Time frame: Week 12

  4. Proportion of participants with clinical remission using the 3-component mMS at Week 48.

    The Modified Mayo Score (MMS) is a composite score of ulcerative colitis (UC) disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: Endoscopic subscore (ES), scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); Stool frequency subscore (SFS), scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and rectal bleeding subscore (RBS), scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS.

    Time frame: Week 48

  5. Proportion of participants with endoscopic improvement at Week 48.

    Endoscopic improvement is defined as Mayo endoscopic subscore (ES) of 0 or 1. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity.

    Time frame: Week 48

  6. Proportion of participants with HEMI at Week 48

    HEMI is defined as a Geboes score of 3.1 or less and ES of 0 or 1. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation. ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration).

    Time frame: Week48

07

Study locations

30 of 114 sites recruiting
  • Site US-022
    Sun City, Arizona 85351, United States
    Recruiting
  • Site US-018
    San Diego, California 92103, United States
    Recruiting
  • Site US-028
    Bristol, Connecticut 06010, United States
    Recruiting
  • Site US-026
    Orlando, Florida 32825, United States
    Recruiting
  • Site US-005
    Des Plaines, Illinois 60016, United States
    Recruiting
  • Site US-007
    Glenview, Illinois 60026, United States
    Recruiting
  • Site US-020
    Gurnee, Illinois 60031, United States
    Recruiting
  • Site US-008
    Baton Rouge, Louisiana 70809, United States
    Recruiting
  • Site US-011
    Mandeville, Louisiana 70471, United States
    Recruiting
  • Site US-010
    Tupelo, Mississippi 38801, United States
    Recruiting
  • Site US-006
    St Louis, Missouri 63141, United States
    Recruiting
  • Site US-014
    Clifton, New Jersey 07013, United States
    Recruiting
  • Site US-002
    Albany, New York 12206, United States
    Recruiting
  • Site US-016
    Rochester, New York 14618, United States
    Recruiting
  • Site US-025
    Brunswick, Ohio 44212, United States
    Recruiting
  • Site US-023
    Dayton, Ohio 45415, United States
    Recruiting
  • Site US-027
    Westlake, Ohio 44145, United States
    Recruiting
  • Site US-019
    Providence, Rhode Island 02905, United States
    Recruiting
  • Site US-003
    Cordova, Tennessee 38018, United States
    Recruiting
  • Site US-024
    Garland, Texas 75044, United States
    Recruiting
  • Site US-009
    Georgetown, Texas 78628, United States
    Recruiting
  • Site US-030
    Houston, Texas 77024, United States
    Recruiting
  • Site US-015
    Lubbock, Texas 79424, United States
    Recruiting
  • Site US-017
    Mansfield, Texas 760063, United States
    Recruiting
  • Site US-001
    Southlake, Texas 76092, United States
    Recruiting
  • Site US-004
    Tyler, Texas 75701, United States
    Recruiting
  • Site US-013
    Richmond, Virginia 23229, United States
    Recruiting
  • Site US-021
    Bellevue, Washington 98004, United States
    Recruiting
  • Site US-029
    Tacoma, Washington 98405, United States
    Recruiting
  • Site US-012
    Milwaukee, Wisconsin 53215, United States
    Recruiting
  • Site CA-005
    Calgary, Alberta T2N 4L7, Canada
    Not yet recruiting
  • Site CA-004
    Edmonton, Alberta T6K 4E8, Canada
    Not yet recruiting
  • Site CA-006
    Greater Sudbury, Ontario P3C1X3, Canada
    Not yet recruiting
  • Site CA-003
    London, Ontario N6K 1M6, Canada
    Not yet recruiting
  • Site CA-002
    Scarborough Village, Ontario M1B3V4, Canada
    Not yet recruiting
  • Site CA-007
    Montreal, Quebec H1T 2M4, Canada
    Not yet recruiting
  • Site CA-001
    Montreal, Quebec H2X 3E4, Canada
    Not yet recruiting
  • Site CZ-005
    Brno, 602 00, Czechia
    Not yet recruiting
  • Site CZ-002
    Brno, 615 00, Czechia
    Not yet recruiting
  • Site CZ-008
    Havířov, 736 01, Czechia
    Not yet recruiting
  • Site CZ-006
    Hradec Králové, 500 12, Czechia
    Not yet recruiting
  • Site CZ-007
    Prague, 150 00, Czechia
    Not yet recruiting
  • Site CZ-004
    Slaný, 274 01, Czechia
    Not yet recruiting
  • Site FR-003
    Amiens, 80000, France
    Not yet recruiting
  • Site FR-005
    Clermont-Ferrand, 63003, France
    Not yet recruiting
  • Site FR-002
    Neuilly-sur-Seine, 92200, France
    Not yet recruiting
  • Site FR-001
    Nice, 06200, France
    Not yet recruiting
  • Site FR-004
    Saint-Priest-en-Jarez, 42270, France
    Not yet recruiting
  • Site GE-003
    Batumi, Quebec 6010, Georgia
    Not yet recruiting
  • Site GE-007
    Tbilisi, Quebec 0102, Georgia
    Not yet recruiting
  • Site GE-002
    Tbilisi, Quebec 0144, Georgia
    Not yet recruiting
  • Site GE-004
    Tbilisi, Quebec 0159, Georgia
    Not yet recruiting
  • Site GE-008
    Tbilisi, Quebec 0160, Georgia
    Not yet recruiting
  • Site GE-001
    Tbilisi, Quebec 0178, Georgia
    Not yet recruiting
  • Site GE-005
    Tbilisi, Quebec 0180, Georgia
    Not yet recruiting
  • Site GE-006
    Tbilisi, Quebec 0180, Georgia
    Not yet recruiting
  • Site HU-005
    Budapest, 1024, Hungary
    Not yet recruiting
  • Site HU-002
    Budapest, H-1062, Hungary
    Not yet recruiting
  • Site HU-001
    Budapest, H-1088, Hungary
    Not yet recruiting
  • Site HU-004
    Debrecen, H-4025, Hungary
    Not yet recruiting
  • Site HU-007
    Gyöngyös, H-3200, Hungary
    Not yet recruiting
  • Site HU-006
    Tatabánya, H-2800, Hungary
    Not yet recruiting
  • Site HU-003
    Veszprém, 8200, Hungary
    Not yet recruiting
  • Site IT-002
    Bari, 70124, Italy
    Not yet recruiting
  • Site IT-004
    Bologna, 40138, Italy
    Not yet recruiting
  • Site IT-007
    Matera, 75100, Italy
    Not yet recruiting
  • Site IT-009
    Negrar, 37024, Italy
    Not yet recruiting
  • Site IT-001
    Rome, 00128, Italy
    Not yet recruiting
  • Site IT-003
    Rome, 00133, Italy
    Not yet recruiting
  • Site IT-008
    Rome, 00168, Italy
    Not yet recruiting
  • Site IT-006
    Rozzano, 20089, Italy
    Not yet recruiting
  • Site IT-005
    San Giovanni Rotondo, 71013, Italy
    Not yet recruiting
  • Site IT-010
    Turin, 10126, Italy
    Not yet recruiting
  • Site LV-003
    Liepāja, LV-3414, Latvia
    Not yet recruiting
  • Site LV-002
    Riga, LV-1002, Latvia
    Not yet recruiting
  • Site LV-001
    Riga, LV-1012, Latvia
    Not yet recruiting
  • Site PL-014
    Bydgoszcz, 85-794, Poland
    Not yet recruiting
  • Site PL-005
    Elblag, 82-300, Poland
    Not yet recruiting
  • Site PL-006
    Katowice, 40-748, Poland
    Not yet recruiting
  • Site PL-022
    Kielce, 25-375, Poland
    Not yet recruiting
  • Site PL-002
    Krakow, 30-363, Poland
    Not yet recruiting
  • Site PL-016
    Krakow, 31-228, Poland
    Not yet recruiting
  • Site PL-020
    Kłodzko, 57-300, Poland
    Not yet recruiting
  • Site PL-021
    Lodz, 91-495, Poland
    Not yet recruiting
  • Site PL-004
    Lublin, 20-582, Poland
    Not yet recruiting
  • Site PL-008
    Nowy Targ, 34-400, Poland
    Not yet recruiting
  • Site PL-018
    Opole, 45-819, Poland
    Not yet recruiting
  • Site PL-003
    Poznan, 60-529, Poland
    Not yet recruiting
  • Site PL-010
    Sopot, 81-756, Poland
    Not yet recruiting
  • Site PL-012
    Staszów, 28-200, Poland
    Not yet recruiting
  • Site PL-001
    Szczecin, 71-434, Poland
    Not yet recruiting
  • Site PL-015
    Szczecin, 71-685, Poland
    Not yet recruiting
  • Site PL-007
    Torun, 87-100, Poland
    Not yet recruiting
  • Site PL-019
    Tychy, 43-100, Poland
    Not yet recruiting
  • Site PL-017
    Warsaw, 00-189, Poland
    Not yet recruiting
  • Site PL-013
    Warsaw, 04-501, Poland
    Not yet recruiting
  • Site PL-009
    Wroclaw, 52-416, Poland
    Not yet recruiting
  • Site PL-011
    Wroclaw, 53-611, Poland
    Not yet recruiting
  • Site RO-001
    Bucharest, 020125, Romania
    Not yet recruiting
  • Site RO-003
    Bucharest, 021967, Romania
    Not yet recruiting

Showing the first 100 of 114 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 14 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 29, 2026
StartActual
Aug 28, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Jun 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Site US-018 · San Diego, United StatesNot yet recruiting→Recruiting
  • Site US-028 · Bristol, United StatesNot yet recruiting→Recruiting
  • Site US-004 · Tyler, United StatesNot yet recruiting→Recruiting
  • Site US-012 · Milwaukee, United StatesNot yet recruiting→Recruiting
  • Site US-008 · Baton Rouge, United StatesNot yet recruiting→Recruiting
  • Site US-010 · Tupelo, United StatesNot yet recruiting→Recruiting
Show 1 removed
  • Site SK-005 · Prešov, Slovakia
across 2 updates, Oct 21, 2026 – Nov 12, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 3 updates
  1. Nov 12, 2026
    1 site removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Site US-008 · Baton Rouge, United StatesNot yet recruiting→Recruiting
    • Site US-010 · Tupelo, United StatesNot yet recruiting→Recruiting
    Show 1 removed
    • Site SK-005 · Prešov, Slovakia
  2. Oct 21, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Site US-018 · San Diego, United StatesNot yet recruiting→Recruiting
    • Site US-028 · Bristol, United StatesNot yet recruiting→Recruiting
    • Site US-004 · Tyler, United StatesNot yet recruiting→Recruiting
    • Site US-012 · Milwaukee, United StatesNot yet recruiting→Recruiting
  3. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845487
Lead sponsor
Palisade Bio
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Aug 28, 2026
Primary completion
Oct 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PALI-2108

Start the discussion